Topical Application of Hemocoagulase in Total Hip Arthroplasty
MA Sheng-shan,HUANG Cong-wei,SUN Yang,JING Cheng-zhe
Department of Sports Medicine, the First People’s Hospital of Lianyungang, Lianyungang (222000), China;Department of Orthopedics, Nanjing Hospital Affiliated to Nanjing Medical University (Nanjing First Hospital) (Nanjing 210000)
Abstract:
Objective To investigate the effectiveness and safety of topical application of hemocoagulase in total hip arthroplasty (THA). Methods A total of 45 patients undergoing total hip arthroplasty were enrolled in this randomized controlled trial. Each group contains 15 patients. Patients in group A were not given any hemostatic agents while 50 mL tranexamic acid was injected intra-articular in group B and 12 mL hemocoagulase in group C. The sex, age, body mass index (BMI), preoperative hemoglobin (Hb), platelets, coagulation routine, intraoperative blood loss, postoperative drainage in 24 h, blood transfusions rate, and postoperative hemoglobin of patients in each group were collected. Clinical symptoms of deep venous thrombosis (DVT), pulmonary embolism (PE), pneumonia and incision infection were observed. Results There was no statistic signi?cance in intraoperative blood loss, incidence of DVT, pneumonia, incision infection and other complications in the three groups (P > 0. 05), but there was statistic signi?cance in postoperative drainage in 24 h [(396. 7± 139.5)mL vs ( 303. 3± 91. 5) mL vs ( 206. 7± 106. 7) mL, P < 0. 05], blood transfusions rate ( 33. 3% vs 13. 3% vs 0,P<0.05) and postoperative hemoglobin [(87.9±10.6) g/L vs (96.9±10.7) g/L vs (107.2±11.1) g/L, P<0.05]. No complication occured in the three groups. Conclusion Topical use of hemocoagulase following THA is effective in reducing blood loss and transfusion rate without increasing the risk of DVT and other substantial complications.
